Holen Sie sich die Stockscreener-App
4.81
4.66%
-0.235
Handel nachbörslich:
4.89
0.08
+1.66%
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara Inc CCO Braden Parker Withholds 29,323 Shares for RSU Tax Settlement - Kalkine Media
Form 4 Savara Inc For: 25 September By Investing.com - Investing.com Nigeria
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster? - RTTNews
Savara Inc (YB4P.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Savara Pharmaceuticals stock holds near its yearly low - AD HOC NEWS
Savara, Inc. (SVRA) Stock Analysis: Exploring a Potential 101.80% Upside in Biotech Investment - DirectorsTalk Interviews
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution - careplusvn.com
Savara (SVRA) Institutional Ownership 2026 - MarketBeat
SVRA Q2 2026 Earnings: Wider-than-Expected Loss of $0.16 Per Share, Shares Rise 2.98% on Pipeline OptimismConsensus Miss Rate - dars.gov.et
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)? - moomoo.com
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st
Savara stock holds steady as investors focus on lead lung therapy - ad-hoc-news.de
Savara Grants Equity Awards to Eight New Employees - MyChesCo
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Savara (SVRA) Results at a Glance: Profit Per Share Falls Below Its Benchmark for This Review; Market Response: Shares Finish 0.72% Higher for the Current SessionFinancial Health Score - careplusvn.com
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)? - simplywall.st
Savara presents molgramostim data at ERS Congress in September By Investing.com - Investing.com Canada
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 - Yahoo Finance
Savara (SVRA) Stock: Ends Up by 1.82% at $5.59 in the Current Update; Level Watch: the $5.31 to $5.87 Range Remains in Focus in the Latest SessionRetail Volume - dars.gov.et
Savara (SVRA) Trading: Posts a 1.82% Gain to $5.59 in Latest Trading; Next Test: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateWyckoff Spring - dars.gov.et
Savara Announces New Employment Inducement GrantAugust 20, 2026 - BioSpace
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Outlook Update - dars.gov.et
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11 - Moomoo
Savara (SVRA) Advances 2.09% to $5.38 as Aerosol Therapy Momentum BuildsStock Analysis - vinanet.vn
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Pipeline InvestmentPeak Earnings Alert - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Triple Top - vinanet.vn
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - marketbeat.com
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in SightPrice Momentum Stocks - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Revenue Weighted - Vinanet
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. Announces Q2 2026 Financial Results with Increased Net Losses - Kalkine Media
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Q2 loss widens as operating expenses rise - TradingView
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary - TradingView
BRIEF-Savara Q2 Net Income USD -40.228 Million - TradingView
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC - MarketBeat
Savara Inc (YB4P.SG) recent insider transactions - au.finance.yahoo.com
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 88.90% Potential Upside - DirectorsTalk Interviews
Savara investors brace for earnings ahead of crucial FDA review By Investing.com - Investing.com Nigeria
Savara (SVRA) to Announce Quarterly Earnings on Wednesday - MarketBeat
SVRA Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):